初次二尖瓣修复失败后:再修复与置换的结局比较
共1749例再次手术,其中再修复410例(23.4%),置换1339例(76.6%)。再修复组未调整总生存优于置换组(HR 3.54;95%CI 2.01-6.24;P<.001),经广泛风险调整(HR 1.96;95%CI 1.10-3.52;P=.022)和倾向评分匹配(HR 1.95;95%CI 1.01-3.82;P=.045)后生存获益持续存在。再修复组术后并发症或死亡更低(6.8% vs 11%;P=.042),术后卒中或再手术无差异。
要点
- 再修复组未调整总生存优于置换组(HR 3.54;95%CI 2.01-6.24;P<.001)。
- 风险调整后生存获益持续(HR 1.96;95%CI 1.10-3.52;P=.022)。
- 再修复组术后并发症或死亡更低(6.8% vs 11%;P=.042)。
核心结论
- 退行性二尖瓣反流初次修复失败后,再修复相比置换具有更优的中期生存。
- 在符合条件的复发性二尖瓣反流患者中,再修复可能更受推荐。
研究设计与样本
- 纳入因退行性二尖瓣反流行孤立二尖瓣修复、30天后再次手术的患者。
- 共1749例再次手术患者,再修复410例(23.4%),置换1339例(76.6%)。
- 采用多变量logistic回归分析再修复预测因素,Cox回归分析纵向生存,并链接国家死亡索引和CMS数据。
主要发现
- 再修复组未调整总生存优于置换组(HR 3.54;95%CI 2.01-6.24;P<.001)。
- 经广泛风险调整后生存获益持续(HR 1.96;95%CI 1.10-3.52;P=.022)。
- 倾向评分匹配后生存获益持续(HR 1.95;95%CI 1.01-3.82;P=.045)。
- 再修复组术后并发症或死亡更低(6.8% vs 11%;P=.042)。
- 术后卒中或再手术无差异。
临床怎么用
- 对于退行性二尖瓣反流初次修复失败后需再次手术的患者,若条件允许,可优先考虑再修复。
- 再修复与更优的中期生存相关,且术后并发症或死亡更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the increasing incidence of primary mitral valve repair, the number of patients requiring reintervention for degenerative mitral regurgitation (MR) has also increased. We examined whether mitral valve re-repair is superior to replacement after failed repair for degenerative MR. METHODS: Patients undergoing isolated surgical mitral valve repair for degenerative MR were identified from The Society of Thoracic Surgeons Adult Cardiac Surgery Database between July 2011 and December 2023. Failed mitral repair was defined as any subsequent reoperations after 30 days on the mitral valve. Predictors for re-repair were calculated by multivariable logistic regression, and longitudinal survival was analyzed with linkage to the National Death Index and the Centers for Medicare & Medicaid Services data using Cox regression. RESULTS: Overall, 1749 patients required reoperation on the mitral valve during the study period, including 410 (23.4%) re-repairs and 1339 (76.6%) replacements. Unadjusted overall survival was superior for patients undergoing re-repair compared with replacement (hazard ratio [HR], 3.54; 95% CI, 2.01-6.24; P < .001). This survival benefit persisted even after extensive risk adjustment (HR, 1.96; 95% CI, 1.10-3.52; P = .022) and propensity score matching (HR, 1.95; 95% CI, 1.01-3.82; P = .045) controlling for patient and valve-related characteristics. Re-repair patients had lower postoperative morbidity or mortality (6.8% vs 11%; P = .042), with no differences in postoperative stroke or reoperation. CONCLUSIONS: In this largest to date analysis of reoperations for degenerative MR, those undergoing re-repair were found to have superior intermediate-term survival compared with mitral valve replacement. These findings suggest that re-repair may be preferred in eligible patients with recurrent MR.
引用
- Ibrahim ME, Toubat O, Sperry AE, et al. Outcomes of Re-Repair vs Replacement After Failed Primary Mitral Regurgitation Repair: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis. Ann Thorac Surg. 2025. PMID: 41285269. doi:10.1016/j.athoracsur.2025.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。